Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people move up a Mounjaro dose after four weeks at their current strength, provided they're tolerating it well and their prescriber agrees the increase is appropriate. That four-week interval is built into the licensed titration schedule, but it's a minimum floor, not a deadline. Treatment starts at 2.5mg (a dose designed to let your system adjust rather than to produce weight loss) and progresses through 5mg, 7.5mg, 10mg, 12.5mg and 15mg in steps timed by how you're responding, both in terms of side effects and how your body is settling. These are prescription-only medicines, which means the decision about when to increase rests with a qualified prescriber who knows your history, not a general rule applied to everyone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: your first Mounjaro pen is nearly finished. You've noticed some changes (appetite a little quieter, maybe a few kilos shifted) but you're still getting waves of nausea after the weekly injection. You're four weeks in and you know the 5mg pen exists. Is it time?
Probably not yet, in that scenario. The four-week mark is the earliest a dose increase is licensed, not a prompt to increase automatically. If nausea is still noticeably affecting your week, your body is telling you it needs more time at 2.5mg. Pushing through too quickly doesn't improve results; it usually means worse side effects and, for some people, having to step back down. The starter dose exists to settle your system first, weight loss comes later, as the dose climbs toward the therapeutic range.
The more useful question isn't "have four weeks passed?" but "am I tolerating this comfortably enough that an increase makes sense?" Your prescriber is the right person to answer that with you. If you want to think it through before that conversation, our guide on when you should go up a dose on Mounjaro can help you frame things clearly.
Mounjaro's six licensed strengths aren't arbitrary. Each one sits roughly 2.5mg above the last, and each step gives your gut (and the rest of your physiology) time to recalibrate. The full Mounjaro treatment overview covers how the medicine works, but in terms of the schedule: 2.5mg for at least four weeks, then 5mg for at least four weeks, and so on up to 15mg as the ceiling.
"At least" is the operative phrase. NICE's appraisal of tirzepatide and the prescribing information are both clear that some people take longer at each rung, and that's fine. A prescriber might keep you at 7.5mg for eight or even twelve weeks if your weight loss is progressing steadily and your side effects are manageable. There's no prize for reaching 15mg quickly. What matters is finding the dose where you're losing weight at a rate that suits your health goals while still being able to eat properly and live normally. You can read more about the 5mg transition specifically at when to move from 2.5mg to 5mg.
One practical note: if a planned increase falls near a bank holiday, a long weekend away, or any week where you'd struggle to monitor how you're feeling closely, it's often worth holding the increase until things are steadier. Starting a new dose mid-holiday with no easy access to support is rarely the right call.
Several things can mean an increase doesn't happen at the four-week mark, and none of them signal failure. The most common is ongoing gastrointestinal side effects: nausea, loose stools or reflux that haven't settled. These are reported widely across tirzepatide clinical trials and are the primary reason titration is cautious by design. If you're weighing up whether your symptoms have settled enough to move forward, our page on when to up your Mounjaro dose walks through the key signs to look for before making that call.
Other reasons a prescriber might pause an increase include: inadequate evidence of how you've been responding at the current dose, a recent illness that makes it harder to separate treatment side effects from something else, or a weight-related condition that needs reassessing before the next step. Certain medicines taken alongside Mounjaro may also factor into the conversation, oral contraceptives in particular, because tirzepatide's effect on gastric emptying can reduce pill absorption in the early weeks of treatment and after each dose increase, which is why additional contraception is recommended during those windows. The NHS guidance on weight management injections covers the practical contraception and medication interactions worth knowing about.
The short answer: if your prescriber wants to wait, that's clinical judgement working as it should, not a delay in your progress.
Above 7.5mg, the pattern shifts slightly. Side effects that had calmed down can resurface briefly after each new step, that's normal and usually settles within a couple of weeks. Weight loss often becomes more pronounced too, particularly in the 10–15mg range, which is where the SURMOUNT-1 trial data showed the strongest average results (up to around 20–21% body weight reduction over 72 weeks at 15mg, in adults without diabetes). For those working toward the upper end of the schedule, our Mounjaro 17.5mg page has information on what that stage of treatment involves. Those figures come from the clinical trial published in the New England Journal of Medicine and reflect a specific trial population, individual results vary, and no outcome is guaranteed.
At higher doses, the clinical review before each repeat matters more, not less. At nume, a GPhC-registered prescriber personally reads your response to the current dose before approving any increase, not a checklist, a real clinical assessment. If you're approaching that decision point and want to talk it through, starting a free consultation is the place to begin. You can also explore Mounjaro pricing to understand what private treatment involves, or visit our about us page to learn more about how the service is structured.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.